This work has been developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian ERDF operational program (European Regional Development Fund) 2014-2020.

Regenerative Medicines and their impact on Healthcare: from lab to market

March 2, 2017

 

The ADVANCE(CAT) project, led by the University of Barcelona, was launched to create an accelerator to develop advanced therapies in Catalonia by setting up a network of Catalan centers involved in this type of work. The project aims to innovate and quickly advance from idea to clinical application and/or industrial production of these therapies.

 

This way, the project will develop the right computer tools, establish complementary facilities needed in addition to those already available and automatize and standardize projects and production systems.

 

The project was presented in the BIO-Europe Spring 2017 by Josep Maria Canals (University of Barcelona) in the session 'Regenerative Medicines and their impact on Healthcare: from lab to market'.

 

The main goals set for this project are:

 

  • SWOT and CAME analyses of advanced therapies in Catalonia.

  • Promoting an organizational structure to encourage transversal technology.

  • Conducting the clinical phase of several innovative advanced-therapies projects that include cell and gene therapy and tissue engineering. Although there are already projects in the clinical phase in Europe, ADVANCECAT will develop treatments that include different types of pluripotent and somatic cells, gene modifications, etc.

Share on Facebook
Share on Twitter
Please reload

Follow Us
  • LinkedIn Social Icon
  • Twitter Social Icon